The Trump administration is considering fast-tracking an experimental Covid-19 vaccine being developed by AstraZeneca Plc and Oxford University for use in the United States ahead of the November 3 elections.
A spokeswoman for AstraZeneca said in a statement, “AstraZeneca has not discussed emergency use authorization with the US government and it would be premature to speculate on that possibility.”
AstraZeneca denied having discussed an emergency use authorization for its potential vaccine with US government.
One option being explored would involve the US Food and Drug Administration awarding emergency use authorization in October to the potential vaccine, which was developed by Oxford and licensed to AstraZeneca.
The relatively small UK trial by AstraZeneca was not designed to produce sufficient data of the kind that would be required for emergency authorization in the United States.
The company informed that the late stage Phase 2 and Phase 3 trials for its vaccine candidate are still ongoing in the UK and other markets globally and that it did not anticipate efficacy results until later this year.
White House Chief of staff, Mark Meadows and Steven Mnuchin, Treasury secretary, told Democrats that the administration was considering fast-tracking a vaccine in a July 30 meeting with Nancy Pelosi, the speaker of the House of Representatives.